Related Experiment Video
Updated: Dec 17, 2025
10:21
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
10.4K
[Hypertrophic cardiomyopathy: modern aspects of pharmacologic treatment]
A Y Gudkova1,2, A A Streltsova2, A A Kostareva1,2
1Pavlov Medical University.
Terapevticheskii Arkhiv
|June 30, 2020
Insights
This review covers new insights into the genetic causes and classification of hypertrophic cardiomyopathy (HCM). It also explores updated pharmacologic treatments and disease-specific management strategies for HCM patients.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Hypertrophic cardiomyopathy (HCM) is a complex genetic heart disease.
- Understanding the genetic basis is crucial for diagnosis and treatment.
- Current management strategies are evolving.
Purpose of the Study:
- To review recent advances in the genetic basis of HCM.
- To discuss current classification systems for HCM.
- To summarize pharmacologic treatment options and novel management approaches for HCM.
Main Methods:
- Literature review of recent studies on HCM genetics.
- Analysis of current clinical guidelines and classifications.
- Synthesis of data on pharmacologic interventions and disease-specific management.
Main Results:
- Significant progress has been made in identifying genetic mutations associated with HCM.
- Refined classification systems aid in risk stratification.
- Emerging pharmacologic therapies show promise for targeted treatment.
Conclusions:
- Advances in genetic understanding are transforming HCM classification and management.
- Personalized pharmacologic strategies are becoming central to HCM care.
- Continued research is essential for further improving outcomes in hypertrophic cardiomyopathy.
Abstract:
This article discusses recent advances in understanding genetic basis and classification of hypertrophic cardiomyopathy. Here, we review pharmacologic treatment strategies and new developments in disease - specific management of HCM.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
204
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
204
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
789
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
789
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
252
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
252
01:30Heart Failure V: Medical Management
143
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
143
01:26Heart Failure Drugs: Inotropic Agents
1.1K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
311
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
311